Amphstar Pharmaceuticals, Inc.

AMPH US Health Care Pharmaceuticals
S&P 600
$23.78
+1.02%
Delayed · cached 15 min

Fair value analysis

AMPH
Amphstar Pharmaceuticals, Inc.
Health CarePharmaceuticals
$23.78
Close used for this calculation
$44.92Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
79/100
Profitability21/25
Returns21/25
Balance Sheet15/25
Efficiency22/25
Growth20/25
Strong
Quality radar
79Prof.21/25Ret.21/25Eff.22/25B.Sht15/25Growth20/25

Consensus fair value

$44.92
Below FV
▲ +88.9% against the close used
Model range $21.45 – $60.90
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear$21.45Fair value$44.92Bull$60.90
FairClose
52-week traded range
52W low $16.8752W high $29.40

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading below the consensus fair value

Amphstar Pharmaceuticals, Inc. closed at $23.78, 47.1% below the consensus fair value of $44.92 drawn from 8 valuation models.

Financial DNA score 79/100 — Strong. P/E of 11.7x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation
$49.80
+109.4%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Number
$21.45
-9.8%
√(22.5 × EPS × BVPS)
EPS=2.03, BVPS=10.08 · outside Graham range (P/E 11.7, P/B 2.4) — asset-light, treat as a rough floor
P/E Fair Value
$40.60
+70.7%
EPS × 20x (sector P/E)
EPS=2.03, Sector P/E=20x
Peter Lynch (PEG)
$60.90
+156.1%
EPS × Growth% (PEG = 1 is fair)
EPS=2.03, g=30%
EV/EBITDA
$54.79
+130.4%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=172.05M
Book Value (P/B)
$40.36
+69.7%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=10.08, ROE=22%, g=6%, r=10%
Reverse DCF
$23.78
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: -0.1% | Historical: 32.8%
Margin of Safety
$27.96
+17.6%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=37.28, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Educational data only. Not a recommendation to buy, sell or hold any security.